Digital diagnosis: new tool for detecting skin cancer. by McGovern, Victoria
A 770 VOLUME 111 | NUMBER 14 | November 2003 • Environmental Health Perspectives
Digital
Diagnosis
Environews  Innovations
NewToolforDetectingSkin CancerEnvironmental Health Perspectives • VOLUME 111 | NUMBER 14 | November 2003 A 771
Innovations | Digital Diagnosis
here are tradeoffs to enjoying one’s day in the sun. The obvi-
ous pleasures of outdoor recreation come at the cost of accelerated
aging of the skin, formation of cataracts and other damage to the
eyes, and increased risk of skin cancers. The deadliest of the skin
cancers, melanoma, has been specifically tied to recreational expo-
sure, as during summertime sunbathing and gardening. Although
fatal when allowed to spread, melanoma is easily treated when
diagnosed early. But traditional screening is time-consuming and
labor-intensive, requiring examination of the entire skin for what
may be tiny irregularities. Thus, it is underused. 
However, recent advances may signal the dawn of a new era in
skin cancer detection. The combination of computer science,
applied mathematics, and high-quality, relatively low-cost optics
has allowed the development of new tools that let computers do
the grunt work of skin screening, highlighting potentially cancer-
ous areas of skin for closer examination by clinicians. 
Early Detection Saves Lives
Melanomas are cancers of the cells that produce melanin, the pig-
ment that colors our hair, skin, and eyes. Diagnosis follows an
“ABCD” rubric: the cancer’s loss of normal growth control can
lead moles and other skin spots to become Asymmetric, display
irregular or blurred Borders, develop an uneven or unusual Color,
or change in Diameter. In melanoma, the depth of a lesion’s pene-
tration is an indicator of its severity. When caught at an early stage,
when it is still less than a millimeter thick and confined to the
outer layer of skin, melanoma is among the most curable cancers.
But melanomas that are diagnosed at a later stage, when the
melanocytes have grown through the skin and its underlying fat
and traveled to sites beyond, are deadly. While the majority of skin
cancers are less frequently fatal but still serious basal cell and squa-
mous cell carcinomas, melanoma causes 79% of skin cancer
deaths, according to the American Cancer Society. 
“The fundamental issue of melanoma is to pick it up before it
spreads,” says Scott Menzies, director of the Sydney Melanoma
Diagnostic Centre at Royal Prince Alfred Hospital in Sydney,
Australia. The center is part of the Sydney Melanoma Unit, the 
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Plargest melanoma treatment center in the
world, where more than 10,000 people
with melanoma are treated each year. 
The United Nations Environment
Programme (UNEP) estimates that more
than 130,000 malignant melanomas devel-
op each year worldwide. Although
melanoma strikes people of all races, its
incidence is concentrated in pale-skinned
people, whose relative lack of pigmentation
gives them comparatively less natural pro-
tection from damage by ultraviolet radiation
than those with darker skin. The problem
is especially dramatic in places where
light-skinned people spend time close to
the equator.
Australia, a nearly equatorial country
with a large population from British and
northern European stock, is ground zero
for skin cancer. One in every two
Australians will get skin cancer at some
time. More than 720,000 suspected skin
cancers are removed in Australia each year,
at a cost to the federal government’s widely
used public health services of more than
US$200 million. Of these, about 1 in 30
turns out to be melanoma. In the United
States, according to the American Cancer
Society, more than 54,000 new cases of
melanoma are diagnosed each year.
Physician diagnosis of early melanoma
focuses on physical examination of the skin
surface. But the skin has a daunting array
of freckles, bumps, and irregularities.
Natural variations in
skin color and texture
complicate matters fur-
ther, as does hair. All
these factors make it
difficult to spot subtle
changes that occur over
time. Despite the well-
known need for screen-
ing, studies have shown
that more melanomas
are first identified by
patients themselves
than by physicians.
During the 1990s,
dermoscopy—also
called epiluminescence
microscopy because it
lights and magnifies fea-
tures on the skin’s surface—was developed
as a tool for dermatologists, general practi-
tioners, and other clinicians. Dermoscopy
combines good lighting and a modest mag-
nifying lens in a handheld device to allow
doctors to better view and evaluate features
such as mole color and shape. Looking for
specific dermoscopy features not seen with
the naked eye allows increased diagnostic
accuracy of melanoma and benign moles. 
A dominant tool in this field is the
Austrian product MoleMax II, which uses a
high-quality camera to record images of a
patient’s moles, allowing the physician to
follow and evaluate changes over time.
Cost varies from country to country, but
MoleMax II generally is priced for use in
individual practitioners’ clinics, not just
large medical centers.
Dermoscopy is the standard of care in
many countries in the world, but not in the
United States, where most general practi-
tioners and even dermatologists simply
haven’t yet picked up on the technology.
But some U.S. doctors do use dermoscopy,
with excellent results. Robert Johr, director
of the Pigmented Lesion Clinic at the
University of Miami School of Medicine
and an advocate of greater use of the tech-
nology, says, “The benefit for the at-risk
patient is that I can create a database of
[full-body] images and dermoscopy images
that I can map out and follow over time.”
This allows him to identify potential prob-
lems early.
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SolarScan. This dermoscopy technology uses image analysis including steps such as computerized
border selection (top) and lesion color detection, coupled with established diagnostic criteria, to
identify potential melanomas for closer inspection.
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Advances in computer science and applied
mathematics are now allowing the basic
technology of dermoscopy to be extended
to a more complex application: predicting
whether observed spots are cancerous.
Several teams are working toward comput-
er-assisted diagnosis of melanoma using
different mathematical and analytical
strategies. 
First to reach the market is
SolarScan, a device priced for use by
individual practitioners and devel-
oped by Australian startup Polar-
technics, with assistance from
Australia’s Commonwealth Scientific
and Industrial Research Organisation
(CSIRO) and the Sydney Melanoma
Unit. SolarScan’s strength is in its
image analysis, which has turned
diagnostic criteria used by doctors
into defined “decision trees” that lead
toward or away from a decision to
call a region of skin a potential
melanoma. The company is develop-
ing similar approaches for diagnosing
other optically accessible cancers,
such as cancer of the cervix.
“The way we diagnose [skin can-
cers] clinically is to look at morpho-
logical patterns—we look for patterns
that are different in malignancy,”
Menzies says. SolarScan’s proprietary
software translates that process into
rules that a computer can follow
when characterizing images.
To develop these rules, a team of ana-
lysts headed by Leanne Bischof, who leads
the CSIRO Image Analysis Group, extract-
ed from clinicians exactly what they look
for in diagnosing melanoma. “You have to
get the skin specialists to describe what’s
happening unconsciously when they look at
a lesion—get them to explain explicitly
what the visual pattern is they’re looking
for,” she says. 
Victor Skladnev, a lead engineer on the
project and managing director of
Polartechnics, agrees. “In extrapolating to
medicine, the question was what features in
the melanoma could be . . . translated into
simple rules.” In the end, SolarScan’s com-
puter brain was trained to weigh the many
visual factors that tell a human when to look
closer at a spot, enabling it to make decisions
about when to label the spot a potential
melanoma rather than a harmless freckle. 
MelaFind, a melanoma diagnosis system
currently in phase III clinical trials in the
United States, approaches the problem of
diagnosis with a different strategy. This sys-
tem, being developed by the small New
York company Electro-Optical Sciences
with advice from clinicians at Harvard, the
University of Louisville, and New York
University, uses spectra at 10 wavelengths
to gather multiple views of a skin lesion’s
structure. 
“The longer the wavelength, the deeper
the penetration of light into the skin,”
explains Marek Elbaum, president and CEO
of Electro-Optical Sciences. Using this
approach, MelaFind measures a suspicious
spot’s depth of penetration and estimates
the stage of any potential melanomas that it
identifies. 
MelaFind does not look at the typical
clinical rules for diagnosing melanoma, the
way SolarScan does. Rather, it examines a
skin spot for disorder in how its cells are
assembled—a consistent sign of the out-of-
control growth that characterizes cancer.
The machine moves beyond human com-
prehension of order and disorder, using sta-
tistics to quantitate whether and
how a region of cells is in disarray.
“We are motivated by physi-
cians’ observations,” Elbaum says,
“but the measures that we are
using are completely different.
When a physician is looking at the
image, his brain is not using statis-
tics measures. He is using his brain
and his gestalt to look at [the
spot’s] features. We are looking at
statistical representations of cellu-
lar architecture.” 
Like physicians, both of these
systems will build up experience
over time. But the experience will
be stored in shareable databases,
not an individual practitioner’s
memory.
Continuing Education
Neither SolarScan nor MelaFind
are working toward replacing
physicians. “We have taken the
approach of not pushing out a
[definitive] answer, but rather
parameters that indicate to the doctor,
‘You’d better have a closer look,’”
Skladnev says. The technologies have their
gaps, too—primarily the fact that neither
product works well on nonpigmented
“pink lesions,” which represent about 5%
of melanomas.
But will such systems ever diagnose can-
cer as well as or better than a trained clini-
cian? “There’s not enough data to tell how
good they’re going to be,” says Harold
Rabinovitz, a physician who has done trials
with both SolarScan and MelaFind in his
Florida private practice. The ability of these
systems to diagnose skin cancers with high
sensitivity will come to pass, he says. But
the devices must be “fed” data from many
more cancerous lesions before they will sur-
pass human expertise.
Menzies has a similar view. “You’re
going to need human intervention, but
you’d have to be very pessimistic to believe
that, in a generation, they’re not going to
be better than a clinician,” he predicts.
“The database will just be more experienced
than any clinician.” 
Victoria McGovern
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MelaFind. This technology uses light to penetrate the skin. The
device takes multiple views of suspicious spots, providing informa-
tion on cellular array disorder, an indicator of melanoma.
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